Literature DB >> 24916104

Transcriptional roles of PARP1 in cancer.

Matthew J Schiewer1, Karen E Knudsen2.   

Abstract

Poly (ADP-ribose) polymerase-1 (PARP1) is an abundant, ubiquitously expressed NAD(+)-dependent nuclear enzyme that has prognostic value for a multitude of human cancers. PARP1 activity serves to poly (ADP-ribose)-ylate the vast majority of known client proteins and affects a number of cellular and biologic outcomes, by mediating the DNA damage response (DDR), base-excision repair (BER), and DNA strand break (DSB) pathways. PARP1 is also critically important for the maintenance of genomic integrity, as well as chromatin dynamics and transcriptional regulation. Evidence also indicates that PARP-directed therapeutics are "synthetic lethal" in BRCA1/2-deficient model systems. Strikingly, recent studies have unearthed exciting new transcriptional-regulatory roles for PARP1, which has profound implications for human malignancies and will be reviewed herein. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24916104      PMCID: PMC4134958          DOI: 10.1158/1541-7786.MCR-13-0672

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  97 in total

1.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Authors:  J Chad Brenner; Bushra Ateeq; Yong Li; Anastasia K Yocum; Qi Cao; Irfan A Asangani; Sonam Patel; Xiaoju Wang; Hallie Liang; Jindan Yu; Nallasivam Palanisamy; Javed Siddiqui; Wei Yan; Xuhong Cao; Rohit Mehra; Aaron Sabolch; Venkatesha Basrur; Robert J Lonigro; Jun Yang; Scott A Tomlins; Christopher A Maher; Kojo S J Elenitoba-Johnson; Maha Hussain; Nora M Navone; Kenneth J Pienta; Sooryanarayana Varambally; Felix Y Feng; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

Review 2.  Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal.

Authors:  Mi Young Kim; Tong Zhang; W Lee Kraus
Journal:  Genes Dev       Date:  2005-09-01       Impact factor: 11.361

3.  PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator.

Authors:  Rushad Pavri; Brian Lewis; Tae-Kyung Kim; F Jeffrey Dilworth; Hediye Erdjument-Bromage; Paul Tempst; Gilbert de Murcia; Ronald Evans; Pierre Chambon; Danny Reinberg
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

4.  Poly(ADP-ribose) polymerase 1 participates in the phase entrainment of circadian clocks to feeding.

Authors:  Gad Asher; Hans Reinke; Matthias Altmeyer; Maria Gutierrez-Arcelus; Michael O Hottiger; Ueli Schibler
Journal:  Cell       Date:  2010-09-09       Impact factor: 41.582

5.  Specific binding of poly(ADP-ribose) polymerase-1 to cruciform hairpins.

Authors:  Vladimir N Potaman; Luda S Shlyakhtenko; Elena A Oussatcheva; Yuri L Lyubchenko; Viatcheslav A Soldatenkov
Journal:  J Mol Biol       Date:  2005-05-06       Impact factor: 5.469

6.  Activating the PARP-1 sensor component of the groucho/ TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent neurogenic gene activation pathway.

Authors:  Bong-Gun Ju; Derek Solum; Eun Joo Song; Kong-Joo Lee; David W Rose; Christopher K Glass; Michael G Rosenfeld
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

Review 7.  The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

Authors:  Raga Krishnakumar; W Lee Kraus
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

8.  The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies.

Authors:  Wael Y Mansour; Tim Rhein; Jochen Dahm-Daphi
Journal:  Nucleic Acids Res       Date:  2010-05-18       Impact factor: 16.971

9.  PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway.

Authors:  Raga Krishnakumar; W Lee Kraus
Journal:  Mol Cell       Date:  2010-09-10       Impact factor: 19.328

10.  PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1.

Authors:  Alex Pines; Mischa G Vrouwe; Jurgen A Marteijn; Dimitris Typas; Martijn S Luijsterburg; Medine Cansoy; Paul Hensbergen; André Deelder; Anton de Groot; Syota Matsumoto; Kaoru Sugasawa; Nicolas Thoma; Wim Vermeulen; Harry Vrieling; Leon Mullenders
Journal:  J Cell Biol       Date:  2012-10-08       Impact factor: 10.539

View more
  71 in total

Review 1.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

2.  A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.

Authors:  Jiyeon Choi; Mai Xu; Matthew M Makowski; Tongwu Zhang; Matthew H Law; Michael A Kovacs; Anton Granzhan; Wendy J Kim; Hemang Parikh; Michael Gartside; Jeffrey M Trent; Marie-Paule Teulade-Fichou; Mark M Iles; Julia A Newton-Bishop; D Timothy Bishop; Stuart MacGregor; Nicholas K Hayward; Michiel Vermeulen; Kevin M Brown
Journal:  Nat Genet       Date:  2017-07-31       Impact factor: 38.330

Review 3.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

4.  Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.

Authors:  Yaroslava Karpova; Chao Wu; Ali Divan; Mark E McDonnell; Elizabeth Hewlett; Peter Makhov; John Gordon; Min Ye; Allen B Reitz; Wayne E Childers; Tomasz Skorski; Vladimir Kolenko; Alexei V Tulin
Journal:  Biochem Pharmacol       Date:  2019-03-15       Impact factor: 5.858

Review 5.  Immunotherapy of Prostate Cancer: Facts and Hopes.

Authors:  Marijo Bilusic; Ravi A Madan; James L Gulley
Journal:  Clin Cancer Res       Date:  2017-06-29       Impact factor: 12.531

6.  Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer.

Authors:  Dong Zhou; Jinbin Xu; Cedric Mpoy; Wenhua Chu; Sung Hoon Kim; Huifangjie Li; Buck E Rogers; John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2018-08-24       Impact factor: 2.408

7.  There and Back Again: The Middle Earth of DNA Repair.

Authors:  Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2016-10       Impact factor: 5.852

8.  DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.

Authors:  Daniela Kurfurstova; Jirina Bartkova; Radek Vrtel; Alena Mickova; Alena Burdova; Dusana Majera; Martin Mistrik; Milan Kral; Frederic R Santer; Jan Bouchal; Jiri Bartek
Journal:  Mol Oncol       Date:  2016-03-03       Impact factor: 6.603

Review 9.  DNA Damage Response in Prostate Cancer.

Authors:  Matthew J Schiewer; Karen E Knudsen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

10.  A Plug-and-Play, Drug-on-Pillar Platform for Combination Drug Screening Implemented by Microfluidic Adaptive Printing.

Authors:  Jiannan Li; Wen Tan; Wenwu Xiao; Randy P Carney; Yongfan Men; Yuanpei Li; Gerald Quon; Yousif Ajena; Kit S Lam; Tingrui Pan
Journal:  Anal Chem       Date:  2018-11-13       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.